1ISG-025 Budget impact analysis of biosimilar adalimumab versus reference adalimumab

MLA

M Provencio Del Olmo, et al. “1ISG-025 Budget Impact Analysis of Biosimilar Adalimumab versus Reference Adalimumab.” Section 1: Introductory Statements and Governance, Mar. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........23ba6838b99ac93de2697c65b49d00ea&authtype=sso&custid=ns315887.

APA

M Provencio Del Olmo, C Bustos Morell, N Labrador Andujar, MP Monforte Gasque, JM Gonzalez Puyuelo, & EM Lazaro Gallardo. (2021). 1ISG-025 Budget impact analysis of biosimilar adalimumab versus reference adalimumab. Section 1: Introductory Statements and Governance.

Chicago

M Provencio Del Olmo, C Bustos Morell, N Labrador Andujar, MP Monforte Gasque, JM Gonzalez Puyuelo, and EM Lazaro Gallardo. 2021. “1ISG-025 Budget Impact Analysis of Biosimilar Adalimumab versus Reference Adalimumab.” Section 1: Introductory Statements and Governance, March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........23ba6838b99ac93de2697c65b49d00ea&authtype=sso&custid=ns315887.